Abstract: It is intended to provide a method for producing an NK cell-enriched blood preparation, which is low invasive and is capable of conveniently and rapidly growing NK cells, etc. in blood collected from an organism. The NK cells in blood are stimulated with NK cell growth-stimulating factors comprising an anti-CD16 antibody, OK432, an anti-CD137 antibody, and a cytokine. Then, the blood is cultured at a physiological cell temperature to produce an NK cell-enriched blood preparation.

Abstract: It is intended to provide a method for producing an NK cell-enriched blood preparation, which is low invasive and is capable of conveniently and rapidly growing NK cells, etc. in blood collected from an organism. The NK cells in blood are stimulated with NK cell growth-stimulating factors comprising an anti-CD16 antibody, OK432, an anti-CD137 antibody, and a cytokine. Then, the blood is cultured at a physiological cell temperature to produce an NK cell-enriched blood preparation.

Abstract: Disclosed are: a method for culture of disease antigen specific CTLs and ??T cells in one culture step conveniently and efficiently; and a pharmaceutical agent and a therapeutic/prophylactic method both of which use a cell produced by the method. Blood is collected and peripheral blood mononuclear cells are separated from the blood. Aminobisphosphonate and a disease antigen are added to the peripheral blood mononuclear cells at the beginning of culture, and the cell culture is carried out for a predetermined period to proliferate/induce disease antigen specific CTLs and ??T cells simultaneously until the numbers of the cells reach values that are effective for the treatment of a disease. The CTLs and the ??T cells thus produced are used for the treatment.

Abstract: It is intended to provide a method for producing an NK cell-enriched blood preparation, which is low invasive and is capable of conveniently and rapidly growing NK cells, etc. in blood collected from an organism. The NK cells in blood are stimulated with NK cell growth-stimulating factors comprising an anti-CD16 antibody, OK432, an anti-CD3 antibody, and a cytokine. Then, the blood is cultured at a physiological cell temperature to produce an NK cell-enriched blood preparation.

Abstract: Activated antigen-presenting cells that can induce immunocytes including disease antigen-specific CD8+ CTLs and/or ?? T cells efficiently in vivo and/or in vitro, a medical composition comprising the activated antigen-presenting cells, a treatment and prevention method using the activated antigen-presenting cells, and an induction method of immunocytes including disease antigen-specific CTLs and/or ?? T cells induced using the activated antigen-presenting cell, immunocytes induced by the above-noted method, a medical composition comprising the immunocytes, and a treatment and prevention method using the immunocytes are provided. By co-pulsing antigen-presenting cells with bisphosphonate in addition to the pulse with a disease antigen, the ratio of disease antigen-specific CD8+ CTLs and/or ?? T cells and the number of the disease antigen-specific CD8+ CTLs and the ?? T cells can be increased, compared with the case where the co-pulse with bisphosphonate is not carried out.

Abstract: Activated antigen-presenting cells that can induce immunocytes including disease antigen-specific CD8+ CTLs and/or ?? T cells efficiently in vivo and/or in vitro, a medical composition comprising the activated antigen-presenting cells, a treatment and prevention method using the activated antigen-presenting cells, and an induction method of immunocytes including disease antigen-specific CTLs and/or ?? T cells induced using the activated antigen-presenting cell, immunocytes induced by the above-noted method, a medical composition comprising the immunocytes, and a treatment and prevention method using the immunocytes are provided. By co-pulsing antigen-presenting cells with bisphosphonate in addition to the pulse with a disease antigen, the ratio of disease antigen-specific CD8+ CTLs and/or ?? T cells and the number of the disease antigen-specific CD8+ CTLs and the ?? T cells can be increased, compared with the case where the co-pulse with bisphosphonate is not carried out.

Abstract: A therapeutic method, which includes administering dendritic cells pulsed in vitro with a bisphosphonate-based bone metabolism improving drug, is provided. The dendritic cells may be capable of efficiently activating and/or proliferating ?? T-cells in vivo and/or in vitro. This can permit for easy proliferation of ?? T-cells without burdening a patient, leading to practical applications of immune cell therapies that utilize ?? T-cells.

Abstract: It is intended to provide a method for producing an NK cell-enriched blood preparation, which is low invasive and is capable of conveniently and rapidly growing NK cells, etc. in blood collected from an organism. The NK cells in blood are stimulated with NK cell growth-stimulating factors comprising an anti-CD16 antibody, OK432, an anti-CD3 antibody, and a cytokine. Then, the blood is cultured at a physiological cell temperature to produce an NK cell-enriched blood preparation.

Abstract: The present invention provides dendritic cells capable of efficiently activating and/or proliferating ?? T-cells in vivo and/or in vitro, pharmaceutical compositions comprising said dendritic cells, therapeutic methods and ?? T-cell culture methods utilizing said dendritic cells. By pulsing immature dendritic cells derived from peripheral blood monocytes with a bisphosphonate-based bone metabolism improving drug to enable the cells to activate ?? T-cells, and cultivating them with a cell subset containing ?? T-cells, ?? T-cells can be activated and/or proliferated. This allows for easy proliferation of ?? T-cells without burdening a patient, leading to practical applications of immune cell therapies that utilize ?? T-cells.

Abstract: It is intended to provide a method for producing an NK cell-enriched blood product, the method being less invasive and capable of conveniently and rapidly growing NK cells, etc. in blood collected from an organism. The NK cells in blood are stimulated with NK cell growth-stimulating factors comprising an anti-CD16 antibody, OK432, a bisphosphonate derivative or a salt thereof, or a hydrate thereof, and a cytokine. Then, the blood is cultured at a physiological cell temperature to produce an NK cell-enriched blood product.

Abstract: Disclosed are: a method for culture of disease antigen specific CTLs and ??T cells in one culture step conveniently and efficiently; and a pharmaceutical agent and a therapeutic/prophylactic method both of which use a cell produced by the method. Blood is collected and peripheral blood mononuclear cells are separated from the blood. Aminobisphosphonate and a disease antigen are added to the peripheral blood mononuclear cells at the beginning of culture, and the cell culture is carried out for a predetermined period to proliferate/induce disease antigen specific CTLs and ??T cells simultaneously until the numbers of the cells reach values that are effective for the treatment of a disease. The CTLs and the ??T cells thus produced are used for the treatment.

Abstract: Activated antigen-presenting cells that can induce immunocytes including disease antigen-specific CD8+ CTLs and/or ?? T cells efficiently in vivo and/or in vitro, a medical composition comprising the activated antigen-presenting cells, a treatment and prevention method using the activated antigen-presenting cells, and an induction method of immunocytes including disease antigen-specific CTLs and/or ?? T cells induced using the activated antigen-presenting cell, immunocytes induced by the above-noted method, a medical composition comprising the immunocytes, and a treatment and prevention method using the immunocytes are provided. By co-pulsing antigen-presenting cells with bisphosphonate in addition to the pulse with a disease antigen, the ratio of disease antigen-specific CD8+ CTLs and/or ?? T cells and the number of the disease antigen-specific CD8+ CTLs and the ?? T cells can be increased, compared with the case where the co-pulse with bisphosphonate is not carried out.

Abstract: The present invention provides dendritic cells capable of efficiently activating and/or proliferating ?? T-cells in vivo and/or in vitro, pharmaceutical compositions comprising said dendritic cells, therapeutic methods and ?? T-cell culture methods utilizing said dendritic cells. By pulsing immature dendritic cells derived from peripheral blood monocytes with a bisphosphonate-based bone metabolism improving drug to enable the cells to activate ?? T-cells, and cultivating them with a cell subset containing ?? T-cells, ?? T-cells can be activated and/or proliferated. This allows for easy proliferation of ?? T-cells without burdening a patient, leading to practical applications of immune cell therapies that utilize ?? T-cells.

Abstract: A method for inducing an antigen-specific cytotoxic T lymphocyte (CTL) which recognizes determinants of disease-related antigens, such as from cancer or tumor cells, viral infections, intracellular bacterial infections, or parasitic infections. Lymphocytes are contacted or co-cultured with a cell line which expresses at least one major histocompatibility (MHC) class I molecules and a co-stimulatory molecule, after or while bringing the cell line into contact with a disease antigenic peptide. Alternatively, the lymphocytes may be contacted with a cell line expressing at least one MHC class I molecules and an accessory molecule and presenting an antigen. The CTLs induced by these methods may be used to treat cancer or infectious diseases. Methods for testing the proliferation potential of a lymphocyte sample using cell lines expressing MHC class I molecules and accessory molecules are also disclosed.